Rabizadeh Soghra, Heidari Firouzeh, Karimi Reza, Rajab Armin, Rahimi-Dehgolan Shahram, Yadegar Amirhossein, Mohammadi Fatemeh, Mirmiranpour Hossein, Esteghamati Alireza, Nakhjavani Manouchehr
Endocrinology and Metabolism Research Center (EMRC) Vali-Asr Hospital, Tehran University of Medical Sciences Tehran Iran.
Food Sci Nutr. 2023 Jun 30;11(10):5967-5977. doi: 10.1002/fsn3.3530. eCollection 2023 Oct.
This study evaluated how daily vitamin C administration impacts systemic oxidative stress and inflammation and its safety in T2D patients. This randomized, double-blinded, placebo-controlled, parallel-arm clinical trial included 70 patients with T2D. They were allocated to receive either 500 mg/day of vitamin C or a matching placebo for 8 weeks. Of the 70 subjects assigned to the trial, 57 were included in the statistical analysis (vitamin C: = 32, placebo: = 25). Inflammatory and oxidative markers, including advanced glycation end products (AGEs), malondialdehyde (MDA), advanced oxidation protein products (AOPP), oxidized low-density lipoprotein (ox-LDL), highly sensitive C-reactive protein (hs-CRP), tumor necrosis factor-α (TNF-α), and ferric reducing ability of plasma (FRAP) were measured at baseline and the end of the trial. In addition, vitamin C tolerance was evaluated. A nutritionist visited all participants for a standard diabetic regimen. Following vitamin C supplementation, the serum levels of MDA (-value < .001) and AGEs (-value = .002) demonstrated a significant decrease after controlling for multiple confounders, including age, blood pressure, waist circumference, HbA1C, TG, and LDL-C, while no significant changes were observed for AOPP (-value = .234) and ox-LDL (-value = .480). The FRAP showed an increasing trend as an antioxidant marker but was not statistically significant (-value = .312). The hs-CRP and TNF-α had no significant changes (-value: .899 and .454, respectively). Also, no major adverse events were observed. Vitamin C supplementation may be beneficial in reducing AGEs and MDA in patients with T2D.
本研究评估了每日补充维生素C对2型糖尿病（T2D）患者全身氧化应激和炎症的影响及其安全性。这项随机、双盲、安慰剂对照、平行组临床试验纳入了70例T2D患者。他们被分配接受每日500毫克维生素C或匹配的安慰剂，为期8周。在分配到试验的70名受试者中，57名被纳入统计分析（维生素C组：n = 32，安慰剂组：n = 25）。在基线和试验结束时测量了炎症和氧化标志物，包括晚期糖基化终产物（AGEs）、丙二醛（MDA）、晚期氧化蛋白产物（AOPP）、氧化型低密度脂蛋白（ox-LDL）、高敏C反应蛋白（hs-CRP）、肿瘤坏死因子-α（TNF-α）和血浆铁还原能力（FRAP）。此外，还评估了维生素C耐受性。一名营养师对所有参与者进行标准糖尿病治疗方案的指导。补充维生素C后，在控制了包括年龄、血压、腰围、糖化血红蛋白（HbA1C）、甘油三酯（TG）和低密度脂蛋白胆固醇（LDL-C）等多个混杂因素后，血清MDA水平（P值<0.001）和AGEs水平（P值 = 0.002）显著降低，而AOPP（P值 = 0.234）和ox-LDL（P值 = 0.480）未观察到显著变化。FRAP作为抗氧化标志物呈上升趋势，但无统计学意义（P值 = 0.312）。hs-CRP和TNF-α无显著变化（P值分别为0.899和0.454）。此外，未观察到重大不良事件。补充维生素C可能有助于降低T2D患者的AGEs和MDA水平。
